Lumos Pharma (NASDAQ:LUMO) Downgraded to “Sell” at Zacks Investment Research


Share on StockTwits

Zacks Investment Research lowered shares of Lumos Pharma (NASDAQ:LUMO) from a hold rating to a sell rating in a research note released on Wednesday morning, Zacks.com reports.

According to Zacks, “Lumos Pharma Inc. is a clinical stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics for rare and neglected diseases. The company’s product pipeline consists of LUM-201 which is in clinical stage. Lumos Pharma Inc., formerly known as NewLink Genetics Corporation, is based in AUSTIN, Texas. “

LUMO has been the topic of a number of other reports. ValuEngine downgraded shares of Lumos Pharma from a strong-buy rating to a buy rating in a research report on Tuesday, December 1st. Cantor Fitzgerald started coverage on shares of Lumos Pharma in a research note on Wednesday, December 2nd. They set an overweight rating and a $32.00 price target for the company. Finally, HC Wainwright raised their price target on shares of Lumos Pharma from $33.00 to $34.00 and gave the stock a buy rating in a research note on Monday, November 23rd. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The stock currently has an average rating of Buy and an average target price of $28.50.

LUMO opened at $21.55 on Wednesday. The firm’s 50-day simple moving average is $22.35 and its 200-day simple moving average is $16.75. The firm has a market cap of $178.80 million, a price-to-earnings ratio of -8.42 and a beta of 1.37. Lumos Pharma has a twelve month low of $6.74 and a twelve month high of $36.72.

Lumos Pharma (NASDAQ:LUMO) last released its earnings results on Tuesday, November 10th. The company reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.86. Lumos Pharma had a negative net margin of 2,053.30% and a negative return on equity of 10.58%. The company had revenue of $0.07 million for the quarter, compared to the consensus estimate of $7.80 million. As a group, sell-side analysts predict that Lumos Pharma will post -1.5 EPS for the current fiscal year.

In related news, major shareholder James E. Flynn sold 29,039 shares of the firm’s stock in a transaction that occurred on Wednesday, January 6th. The shares were sold at an average price of $22.48, for a total transaction of $652,796.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder James E. Flynn sold 106,512 shares of the firm’s stock in a transaction that occurred on Friday, January 8th. The shares were sold at an average price of $22.31, for a total transaction of $2,376,282.72. The disclosure for this sale can be found here. 15.90% of the stock is currently owned by company insiders.

A hedge fund recently raised its stake in Lumos Pharma stock. Texas Yale Capital Corp. lifted its holdings in Lumos Pharma, Inc. (NASDAQ:LUMO) by 6.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 16,000 shares of the company’s stock after buying an additional 1,000 shares during the period. Texas Yale Capital Corp. owned about 0.19% of Lumos Pharma worth $221,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 41.49% of the company’s stock.

About Lumos Pharma

Lumos Pharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for severe, rare, and genetic diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency.

Featured Story: Stock Split

Get a free copy of the Zacks research report on Lumos Pharma (LUMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Lumos Pharma (NASDAQ:LUMO)

Receive News & Ratings for Lumos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.